Brief: Heidelberg Pharma Says FDA Allows Start Of Phase I/IIa Trial With ATAC Candidate HDP-101

Heidelberg Pharma AG

04/02/2021 09:58

Feb 4 (Reuters) - HEIDELBERG PHARMA AG  HPHA.DE :
    * FDA ALLOWS HEIDELBERG PHARMA TO START A PHASE I/IIA
CLINICAL
TRIAL WITH ATAC CANDIDATE HDP-101
    * US FOOD AND DRUG ADMINISTRATION (FDA) HAS INFORMED COMPANY
IT IS
SAFE TO PROCEED WITH PHASE I/IIA STUDY WITH BCMA ANTIBODY
TARGETED AMANITIN CONJUGATE, HDP-101 THAT WAS SUBMITTED UNDER
ITS US IND.
    * FIRST PART OF TRIAL IS A PHASE I DOSE ESCALATION STUDY TO
DETERMINE MAXIMUM TOLERATED DOSE OF HDP-101
    * EXPECTS FIRST PATIENT TO BE ENROLLED AND FIRST DOSE TO BE
ADMINISTERED IN Q2 OF 2021.

Source text for Eikon:  ID:nEQ3trsmwa 
Further company coverage:  HPHA.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))